Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For patients with Parkinson's disease:
- People diagnosed with idiopathic (no known cause) Parkinson's disease, confirmed using a specific set of recognised diagnostic guidelines known as the UKPDSBB criteria
- People whose Parkinson's disease is at an early stage (Stage I or II on the Hoehn and Yahr scale, which measures how advanced the condition is)
- People who are not currently taking any dopaminergic medications (drugs that affect dopamine levels, commonly used to treat Parkinson's)
- People whose Parkinson's disease has been developing for up to 5 years
- People without significant memory or thinking difficulties (scoring above 24 on a standard cognitive test called the MoCA)
- Men or women between 18 and 75 years of age
- People who have read, understood, and signed a consent form agreeing to take part
- People who are enrolled in a French social security scheme
For healthy volunteers (control group):
- Men or women between 18 and 75 years of age
- People enrolled in a French social security scheme
- People who have given their written consent to take part
Who may not be able to join:
For patients with Parkinson's disease:
- People whose tremors are severe enough to make an MRI scan impossible to carry out
- People who cannot safely have an MRI scan — for example, those with metal implants or electronic devices in the body (such as a pacemaker, neurostimulator, cochlear implant, or certain prostheses), or people with claustrophobia (fear of enclosed spaces)
- People currently taking medications that may affect brain chemistry, including antidepressants, antipsychotics (neuroleptics), benzodiazepines, or anti-epileptic drugs
- Women who are pregnant
- People already receiving deep brain stimulation treatment
- People under legal guardianship or court-ordered protection
- People currently excluded from or enrolled in another research study (confirm with trial site)
For healthy volunteers (control group):
- People living with a progressive neurological or psychiatric condition
- People who cannot safely have an MRI scan — for example, those with metal implants or electronic devices in the body (such as a pacemaker, neurostimulator, cochlear implant, or certain prostheses), or people with claustrophobia
- People currently taking medications that may affect brain chemistry, including antidepressants, antipsychotics (neuroleptics), benzodiazepines, or anti-epileptic drugs
- Women who are pregnant
- People under legal guardianship or court-ordered protection
- People currently excluded from or enrolled in another research study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ana Rachel MARQUES, University Hospital, Clermont-Ferrand
Phone: 334.73.754.963
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Glutamate concentration (mmol.L-1) measured in the putamen
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.